Sfoglia per Autore
The therapeutic management of gut barrier leaking: The emerging role for mucosal barrier protectors
2015-01-01 Lopetuso, L. R.; Scaldaferri, F.; Bruno, G.; Petito, V.; Franceschi, F.; Gasbarrini, A.
Role and mechanisms of action of Escherichia coli nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update
2016-01-01 Scaldaferri, F.; Gerardi, V.; Mangiola, F.; Lopetuso, L. R.; Pizzoferrato, M.; Petito, V.; Papa, A.; Stojanovic, J.; Poscia, A.; Cammarota, G.; Gasbarrini, A.
Bacillus clausii and gut homeostasis: state of the art and future perspectives
2016-01-01 Lopetuso, L. R.; Scaldaferri, F.; Franceschi, F.; Gasbarrini, A.
Direct effect of infliximab on intestinal mucosa sustains mucosal healing: Exploring new mechanisms of action
2016-01-01 Petito, V.; Lopetuso, L. R.; Arena, V.; Stigliano, E.; Boninsegna, A.; Bibbò, S.; Poscia, A.; Alfieri, S.; Rosa, F.; Amato, A.; Cammarota, G.; Papa, A.; Sgambato, A.; Gasbarrini, A.; Scaldaferri, F.
Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises from a First Meta-Analysis
2016-01-01 Scaldaferri, F.; Pecere, S.; Petito, V.; Zambrano, D.; Fiore, L.; Lopetuso, L. R.; Schiavoni, E.; Bruno, G.; Gerardi, V.; Laterza, L.; Pizzoferrato, M.; Ianiro, G.; Stojanovic, J.; Poscia, A.; Papa, A.; Sterbini, F. P.; Sanguinetti, M.; Masucci, L.; Cammarota, G.; Gasbarrini, A.
Gut Virome and Inflammatory Bowel Disease
2016-01-01 Lopetuso, L. R.; Ianiro, G.; Scaldaferri, F.; Cammarota, G.; Gasbarrini, A.
Rifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation
2016-01-01 Ponziani, F. R.; Pecere, S.; Lopetuso, L.; Scaldaferri, F.; Cammarota, G.; Gasbarrini, A.
High dose amoxicillin-based first line regimen is equivalent to sequential therapy in the eradication of H. Pylori infection
2016-01-01 Franceschi, F.; Ojetti, V.; Gabrielli, M.; Petruzziello, C.; Tortora, A.; Gasbarrini, G.; Lopetuso, L. R.; Scaldaferri, F.; Gasbarrini, A.
Epidemiological evaluation of acute gastroenteritis and therapeutic approaches in Middle East Countries
2016-01-01 Ayoub, D.; Lopetuso, L. R.; Chamseddine, F.; Dajani, A.; Lahiri, K.; Mahmoud, H.; Miqdady, M. S.; Zirizzotti, G.; Sultan, M. A.; Franceschi, F.; Gasbarrini, A.
Ulcerative colitis
2016-01-01 Lopetuso, L.; Gasbarrini, A.
Gut microbiota modulation and mucosal immunity: Focus on Rifaximin
2016-01-01 Lopetuso, L. R.; Petito, V.; Scaldaferri, F.; Gasbarrini, A.
The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin
2016-01-01 Ponziani, F. R.; Scaldaferri, F.; Petito, V.; Paroni Sterbini, F.; Pecere, S.; Lopetuso, L. R.; Palladini, A.; Gerardi, V.; Masucci, L.; Pompili, M.; Cammarota, G.; Sanguinetti, M.; Gasbarrini, A.
Infliximab does not increase colonic cancer risk associated to murine chronic colitis
2016-01-01 Lopetuso, L. R.; Petito, V.; Zinicola, T.; Graziani, C.; Gerardi, V.; Arena, V.; Caristo, M. E.; Poscia, A.; Cammarota, G.; Papa, A.; Cufino, V.; Sgambato, A.; Gasbarrini, A.; Scaldaferri, F.
Nodular lymphoid hyperplasia: A marker of low-grade inflammation in irritable bowel syndrome?
2016-01-01 Piscaglia, A. C.; Laterza, L.; Cesario, V.; Gerardi, V.; Landi, R.; Lopetuso, L. R.; Calò, G.; Fabbretti, G.; Brisigotti, M.; Stefanelli, M. L.; Gasbarrini, A.
Gut Microbiota: A Key Modulator of Intestinal Healing in Inflammatory Bowel Disease
2016-01-01 Lopetuso, L. R.; Petito, V.; Zambrano, D.; Orlando, D.; Dal Lago, A.; Serrichhio, L.; Papa, A.; Gasbarrini, A.; Scaldaferri, F.
Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab
2017-01-01 Scaldaferri, F.; D‘ambrosio, D.; Holleran, G.; Poscia, A.; Petito, V.; Lopetuso, L.; Graziani, C.; Laterza, L.; Pistone, M. T.; Pecere, S.; Currò, D.; Gaetani, E.; Armuzzi, A.; Papa, A.; Cammarota, G.; Gasbarrini, A.
Nutrition and IBD: Malnutrition and/or Sarcopenia? A Practical Guide
2017-01-01 Scaldaferri, F.; Pizzoferrato, M.; Lopetuso, L. R.; Musca, T.; Ingravalle, F.; Sicignano, L. L.; Mentella, M.; Miggiano, G.; Mele, M. C.; Gaetani, E.; Graziani, C.; Petito, V.; Cammarota, G.; Marzetti, E.; Martone, A.; Landi, F.; Gasbarrini, A.
Gut microbiota and inflammatory bowel disease: So far so gut!
2017-01-01 Holleran, G.; Lopetuso, L. R.; Ianiro, G.; Pecere, S.; Pizzoferrato, M.; Petito, V.; Graziani, C.; Mcnamara, D.; Gasbarrini, A.; Scaldaferri, F.
The innate and adaptive immune system as targets for biologic therapies in inflammatory bowel disease
2017-01-01 Holleran, G.; Lopetuso, L.; Petito, V.; Graziani, C.; Ianiro, G.; Mcnamara, D.; Gasbarrini, A.; Scaldaferri, F.
Proteobacteria: A common factor in human diseases
2017-01-01 Rizzatti, G.; Lopetuso, L. R.; Gibiino, G.; Binda, C.; Gasbarrini, A.
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
The therapeutic management of gut barrier leaking: The emerging role for mucosal barrier protectors | 2015 | Lopetuso, L. R.; Scaldaferri, F.; Bruno, G.; Petito, V.; Franceschi, F.; Gasbarrini, A. | |
Role and mechanisms of action of Escherichia coli nissle 1917 in the maintenance of remission in ulcerative colitis patients: an update | 2016 | Scaldaferri, F.; Gerardi, V.; Mangiola, F.; Lopetuso, L. R.; Pizzoferrato, M.; Petito, V.; Papa, A.; Stojanovic, J.; Poscia, A.; Cammarota, G.; Gasbarrini, A. | |
Bacillus clausii and gut homeostasis: state of the art and future perspectives | 2016 | Lopetuso, L. R.; Scaldaferri, F.; Franceschi, F.; Gasbarrini, A. | |
Direct effect of infliximab on intestinal mucosa sustains mucosal healing: Exploring new mechanisms of action | 2016 | Petito, V.; Lopetuso, L. R.; Arena, V.; Stigliano, E.; Boninsegna, A.; Bibbò, S.; Poscia, A.; Alfieri, S.; Rosa, F.; Amato, A.; Cammarota, G.; Papa, A.; Sgambato, A.; Gasbarrini, A.; Scaldaferri, F. | |
Efficacy and Mechanisms of Action of Fecal Microbiota Transplantation in Ulcerative Colitis: Pitfalls and Promises from a First Meta-Analysis | 2016 | Scaldaferri, F.; Pecere, S.; Petito, V.; Zambrano, D.; Fiore, L.; Lopetuso, L. R.; Schiavoni, E.; Bruno, G.; Gerardi, V.; Laterza, L.; Pizzoferrato, M.; Ianiro, G.; Stojanovic, J.; Poscia, A.; Papa, A.; Sterbini, F. P.; Sanguinetti, M.; Masucci, L.; Cammarota, G.; Gasbarrini, A. | |
Gut Virome and Inflammatory Bowel Disease | 2016 | Lopetuso, L. R.; Ianiro, G.; Scaldaferri, F.; Cammarota, G.; Gasbarrini, A. | |
Rifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation | 2016 | Ponziani, F. R.; Pecere, S.; Lopetuso, L.; Scaldaferri, F.; Cammarota, G.; Gasbarrini, A. | |
High dose amoxicillin-based first line regimen is equivalent to sequential therapy in the eradication of H. Pylori infection | 2016 | Franceschi, F.; Ojetti, V.; Gabrielli, M.; Petruzziello, C.; Tortora, A.; Gasbarrini, G.; Lopetuso, L. R.; Scaldaferri, F.; Gasbarrini, A. | |
Epidemiological evaluation of acute gastroenteritis and therapeutic approaches in Middle East Countries | 2016 | Ayoub, D.; Lopetuso, L. R.; Chamseddine, F.; Dajani, A.; Lahiri, K.; Mahmoud, H.; Miqdady, M. S.; Zirizzotti, G.; Sultan, M. A.; Franceschi, F.; Gasbarrini, A. | |
Ulcerative colitis | 2016 | Lopetuso, L.; Gasbarrini, A. | |
Gut microbiota modulation and mucosal immunity: Focus on Rifaximin | 2016 | Lopetuso, L. R.; Petito, V.; Scaldaferri, F.; Gasbarrini, A. | |
The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin | 2016 | Ponziani, F. R.; Scaldaferri, F.; Petito, V.; Paroni Sterbini, F.; Pecere, S.; Lopetuso, L. R.; Palladini, A.; Gerardi, V.; Masucci, L.; Pompili, M.; Cammarota, G.; Sanguinetti, M.; Gasbarrini, A. | |
Infliximab does not increase colonic cancer risk associated to murine chronic colitis | 2016 | Lopetuso, L. R.; Petito, V.; Zinicola, T.; Graziani, C.; Gerardi, V.; Arena, V.; Caristo, M. E.; Poscia, A.; Cammarota, G.; Papa, A.; Cufino, V.; Sgambato, A.; Gasbarrini, A.; Scaldaferri, F. | |
Nodular lymphoid hyperplasia: A marker of low-grade inflammation in irritable bowel syndrome? | 2016 | Piscaglia, A. C.; Laterza, L.; Cesario, V.; Gerardi, V.; Landi, R.; Lopetuso, L. R.; Calò, G.; Fabbretti, G.; Brisigotti, M.; Stefanelli, M. L.; Gasbarrini, A. | |
Gut Microbiota: A Key Modulator of Intestinal Healing in Inflammatory Bowel Disease | 2016 | Lopetuso, L. R.; Petito, V.; Zambrano, D.; Orlando, D.; Dal Lago, A.; Serrichhio, L.; Papa, A.; Gasbarrini, A.; Scaldaferri, F. | |
Body mass index influences infliximab post-infusion levels and correlates with prospective loss of response to the drug in a cohort of inflammatory bowel disease patients under maintenance therapy with Infliximab | 2017 | Scaldaferri, F.; D‘ambrosio, D.; Holleran, G.; Poscia, A.; Petito, V.; Lopetuso, L.; Graziani, C.; Laterza, L.; Pistone, M. T.; Pecere, S.; Currò, D.; Gaetani, E.; Armuzzi, A.; Papa, A.; Cammarota, G.; Gasbarrini, A. | |
Nutrition and IBD: Malnutrition and/or Sarcopenia? A Practical Guide | 2017 | Scaldaferri, F.; Pizzoferrato, M.; Lopetuso, L. R.; Musca, T.; Ingravalle, F.; Sicignano, L. L.; Mentella, M.; Miggiano, G.; Mele, M. C.; Gaetani, E.; Graziani, C.; Petito, V.; Cammarota, G.; Marzetti, E.; Martone, A.; Landi, F.; Gasbarrini, A. | |
Gut microbiota and inflammatory bowel disease: So far so gut! | 2017 | Holleran, G.; Lopetuso, L. R.; Ianiro, G.; Pecere, S.; Pizzoferrato, M.; Petito, V.; Graziani, C.; Mcnamara, D.; Gasbarrini, A.; Scaldaferri, F. | |
The innate and adaptive immune system as targets for biologic therapies in inflammatory bowel disease | 2017 | Holleran, G.; Lopetuso, L.; Petito, V.; Graziani, C.; Ianiro, G.; Mcnamara, D.; Gasbarrini, A.; Scaldaferri, F. | |
Proteobacteria: A common factor in human diseases | 2017 | Rizzatti, G.; Lopetuso, L. R.; Gibiino, G.; Binda, C.; Gasbarrini, A. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile